Skip to main content

Table 3 Associates with bone loss in 92 rheumatoid arthritis patients followed for 10 years

From: Generalized bone loss in early rheumatoid arthritis patients followed for ten years in the biologic treatment era

 

Change in bone mineral density

 

Femoral neck

Total hip

Spine L1-4

 

0-2 yrs

2-10 yrs

0-2 yrs

2-10 yrs

0-2 yrs

2-10 yrs

 

Beta

Beta

Beta

Beta

Beta

Beta

 

p value

p value

p value

p value

p value

p value

Age (yrs)

-

-

-

-

-

B 0.244 P = 0.048

Women (N/Y)

-

B-0.029 P = 0.027

-

B-0.039 P = 0.004

-

B-0.104 P = 0.000

Menopause (N/Y)

-

B-0.033 P = 0.049

B 0.016 P = 0.076

B-0.053 P = 0.003

-

B-0.051 P = 0.063

Smoking (N/Y)

-

B-0.028 p = 0.036

-

B-0.024 P = 0.080

-

-

RF (N/Y)

-

B-0.030 P = 0.030

-

B-0.029 P = 0.047

-

B-0.053 P = 0.044

MHAQ (0–3)

B −0.027 p = 0.034

-

-

-

-

-

ESR (mm/hr)

-

-

-

-

B-0.189 P = 0.092

 

DAS28ESR3

B −0.010 P = 0.030

B-0.015 P = 0.057

-

B-0.016 P = 0.055

B-0.013 P = 0.037

-

Ever use of biologic DMARDs (N/Y)

B-0.023 P = 0.024

-

B-0.019 P = 0.058

-

B-0.023 P = 0.091

B-0.052 P = 0.039

Cumulative equivalent prednisolon (gram)

B-0.002 P = 0.024

-

B-0.003 P = 0.003

-

-

-

  1. Variables are tested for their association with change in hip and spine bone density for the follow up periods 0–2 years and 2–10 years in early rheumatoid arthritis patients using univariate linear regression analysis. Unstandardized Beta values are only shown for variables with a p value ≤ 0.1.
  2. Yrs: Years; N/Y: No/yes; RF: Rheumatoid factor; MHAQ: Modified health assessment questionnaire; ESR: Erythrocyte sedimentation rate; DAS28ESR3: Disease activity score based on 28 joint count (swollen and tender joints) and ESR; DMARDs: Disease modifying anti-rheumatic drugs.